| Document |
Document Title |
|
JP5009152B2 |
The present invention provides a new method of ameliorating and/or treating enteritis induced by radiation therapy, alone or in combination with other therapies, for the treatment oil for example, gastrointestinal malignancies, including...
|
|
JP2012153734A |
To provide methods involving avoiding adverse drug interactions with pirfenidone and CYP inducers, such as smoking.The invention generally relates to improved methods for administering pirfenidone to a patient in need of pirfenidone ther...
|
|
JP4999247B2 |
A composition for the treatment of adhesions that are formed as a result of an inflammatory response comprising an aqueous formulation containing the polysaccharide dextrin in an effective amount. The invention also discloses a method of...
|
|
JP5001906B2 |
Novel synthetic forms of etherified oxidized phospholipids and methods of utilizing same for preventing and treating atherosclerosis and other related disorders are provided. In addition, methods of synthesizing esterified oxidized phosp...
|
|
JP2012149075A |
To provided a method of synthesizing an oxidized phospholipid.The method includes: (a) providing a phospholipid backbone including two fatty acid side chains, wherein at least one of the fatty acid side chains is a mono-unsaturated fatty...
|
|
JP4995406B2 |
Film-forming compositions, as well as methods of making and using, wherein the compositions include an optional active agent, water, a surfactant, and a water-soluble or water-dispersible vinyl polymer comprising amine group-containing s...
|
|
JP4993465B2 |
Described herein are compounds such as macromolecules that have been modified in order to facilitate crosslinking and methods of making and using thereof.
|
|
JP4990583B2 |
Medical devices, and in particular implantable medical devices, may be coated to minimize or substantially eliminate a biological organism's reaction to the introduction of the medical device to the organism. The medical devices may be c...
|
|
JP4988583B2 |
The invention relates to novel anthranilamide pyridinureas as VEGF receptor kinase inhibitors, their production and use as pharmaceutical agents for treating diseases that are triggered by persistent angiogenesis.
|
|
JP4982839B2 |
A vitreous body visualization agent which is to be injected into the eye to visualize the vitreous body by a safe and sure method. The vitreous body visualization agent is prepared by using a polymeric substance having positively or nega...
|
|
JP4986997B2 |
The present invention relates to improved Nanobodies¢ against von Willebrand Factor (vWF), as well as to polypeptides comprising or essentially consisting of one or more of such Nanobodies. The invention also relates to nucleic acids ...
|
|
JP2012136537A |
To provide: a method for the treatment of disease states associated with neovascularization and/or increased vascular permeability; and a medicament for use in causing an anti-angiogenic effect and/or vascular permeability reducing effec...
|
|
JP4980220B2 |
The present invention presents a Kunitz-type recombinant inhibitor obtained from a gene cloned from a cDNA library of salivary glands of the Amblyomma cajennense, and the inhibitor named Amblyomin-X has molecular mass of 13,500 Da.
|
|
JP4970689B2 |
The invention concerns quinazoline derivatives of Formula (I) wherein ring A is phenyl or a 5-or 6-membered heterocyclic ring which may be saturated, partially saturated or unsaturated and may be aromatic or non-aromatic and which contai...
|
|
JP4974902B2 |
A PRP separator-concentrator comprising a housing (2), a separation assembly, and a concentration assembly. The concentration assembly has a concentration sump (162). An axially concentric rigid stationary outlet tube is secured to the h...
|
|
JPWO2010082531A1 |
An object of the present invention is to provide a novel salt form of a compound which exhibits an inhibitory effect on activated blood coagulation factor X and is useful as a prophylactic / therapeutic agent for thrombotic diseases and ...
|
|
JP4969443B2 |
wherein R1, R2, R3, L, X, Y and Z have defined meanings.
|
|
JP2012121902A |
To provide immune therapeutics for infectious or non-infectious immunodeficiencies.There is provided the use of a strain of parapoxvirus ovis belonging to one of NZ2, NZ-7, NZ-10 and orf-11 on the classification for the production of pha...
|
|
JP4960450B2 |
Compounds of formula (I) in free or salt or solvate form, where T1, T2, Ra and Rb have the meanings as indicated in the specification, are useful for treating inflammatory or obstructive airways, pulmonary hypertension, pulmonary fibrosi...
|
|
JP4951185B2 |
The present invention relates to a method of preparing a composition for wound healing, and for repairing and regenerating human and animal tissue, said method comprising the following steps: a. providing a plasmid DNA in substantially p...
|
|
JP4949227B2 |
Disclosed is an interventional device for delivery of therapeutic agents from an angioplasty balloon and from a prosthesis such as an intraluminal stent. The invention also relates to the method of loading the beneficial agents onto the ...
|
|
JP2012101095A |
To provide a synthetic biomaterial including polymeric hydrogels.The method for manufacturing the biomaterial includes a step of combining two or more precursor components of the biomaterial under conditions that allow polymerization of ...
|
|
JP4939751B2 |
The present invention relates to methods of controlling neurological deficits in patients who have undergone cardiopulmonary bypass (CPB) by administering xenon to said patients.
|
|
JP4932132B2 |
The invention relates to compounds of formula I which are useful for elevating the plasma level of growth hormone in a mammal as well as for the treatment of growth hormone secretion deficiency, growth retardation in child and metabolic ...
|
|
JP4925551B2 |
The present invention relates to the use of a compound of formula I: in which, A1 is the radical corresponding to D- or L-Ser, A2 is the radical corresponding to D- or L-Asp or Glu, A3 is the radical corresponding to D- or L-Lys, Arg or ...
|
|
JP2012508575A |
In one aspect, the invention provides isolated populations of cells comprising Foxp3+ natural killer T-cells, methods of generating Foxp3+ natural killer T-cells and methods for suppressing the immune response in specific organs, includi...
|
|
JP2012070738A |
To provide a tribonectin and a method of tribosupplementation carried out by administering tribonectins directly to an injured or arthritic joint.The tribonectin comprises at least one O-linked lubricating moiety which includes a β(1-3)...
|
|
JP4902939B2 |
Composition of Hypochlorous acid characterized because it has the following chemical composition Hypochlorous acid 6.5-7.3% Hydrochloric acid 27.6-28.5% Sodium chloride 13.6-14.2% Sodium hypochlorite 34.8-35.4% Chlorine in solution 7-6.5...
|
|
JP4898447B2 |
The present invention improves significantly the success rate of lithotripsy and reduces the risk of tissue damage, by injecting a temporary plug in front, and optionally behind a concretion (for extracorporeal lithotripsy) or behind a c...
|
|
JP4896327B2 |
The invention identifies PD-1 as a receptor for B7-4. B7-4 can inhibit immune cell activation upon binding to an inhibitory receptor on an immune cell. Accordingly, the invention provides agents for modulating PD-1, B7-4, and the interac...
|
|
JP2012046525A |
To provide a compound and method useful in modulating angiogenesis, and to provide a method of treating or preventing a disease or disorder associated with angiogenesis by administering a polycationic compound.There is provided a salicyl...
|
|
JP4880849B2 |
Benzoylguanidine derivatives (I) and their salts are new. Benzoylguanidine derivatives of formula (I) and their salts are new. [Image] R 1H, halo, NO 2, CN, (X) o-(CH 2) p-(CF 2) q-CF 3, SO m-R 5, COR 6, CONR 6R 7 or SO 2-NR 6R 7; R 3H, ...
|
|
JP4879895B2 |
Novel 1,5 diphenylpyrazole derivatives of the formula (I), in which R1-R6 have the meanings indicated in Claim 1, are HSP90 inhibitors and can be used for the preparation of a medicament for the treatment of diseases in which the inhibit...
|
|
JP2012021034A |
To provide a method of preparing a composition for wound healing, and for repairing and regenerating human and animal tissue.The method includes following steps for: (a) providing a plasmid DNA in substantially pure form, which encodes a...
|
|
JP4855253B2 |
Combined pharmaceutical preparation containing G-CSF and P1GF as the active substances, are useful in the mobilization of blood stem cells in a patient or subject in need thereof.
|
|
JP4851939B2 |
The invention provides peptides that are capable of binding growth factors, as well as peptide amphiphiles comprising certain of these peptides, micellar assemblies of such amphiphiles and related methods of use.
|
|
JP4854070B2 |
An agent and composition for the prevention of and treatments for vasospasm accompanying a bypass operation, which each contains as an active ingredient either a compound represented by the general formula (I) or an acid addition salt or...
|
|
JP2012500245A |
The invention relates to a new use of dabigatran etexilate of formula (I) optionally in the form of the pharmaceutically acceptable salts thereof, and new medicament formulations which may be used for this purpose.
|
|
JP4847011B2 |
The present invention provides for improved compositions comprising a PEGsTNF-R1 which, in addition to having useful higher concentrations, demonstrate decreased viscosity (<400 cP) and improved stability.
|
|
JP4847856B2 |
The invention relates to variants of FVII or FVlla comprising at least one amino acid modification in position 341 relative to HFVII or hFVIIa. The variants exhibit an increased clotting activity, i.e. reduced clotting time, compared to ...
|
|
JP4843079B2 |
Molecular cross-linked gels comprise a variety of biologic and non-biologic polymers, such as proteins, polysaccharides, and synthetic polymers. Such molecular gels may be applied to target sites in a patient's body by extruding the gel ...
|
|
JP4842713B2 |
Molecular cross-linked gels comprise a variety of biologic and non-biologic polymers, such as proteins, polysaccharides, and synthetic polymers. Such molecular gels may be applied to target sites in a patient's body by extruding the gel ...
|
|
JP4837864B2 |
The invention relates to pyridine derivatives of formula (I) wherein the substituents and symbols are defined as indicated in the description, processes for the preparation thereof, their usage in the preparation of a pharmaceutical comp...
|
|
JP4836396B2 |
The invention relates to novel naphthalene derivatives of formula (I) and their use as cannabinoid receptor agonists wherein X, R 1 , R 2 and R 3 are as defined in the description, processes for their production, their use as pharmaceuti...
|
|
JP4834663B2 |
The present invention provides compounds of Formula (I): or a stereoisomer or pharmaceutically acceptable salt or solvate form thereof, wherein the variables A, L, Z, X1, X2, X3, X4, and X5 are as defined herein. The compounds of Formula...
|
|
JP4829449B2 |
This invention is directed to oxoazaheterocyclyl compounds which inhibit Factor Xa, to oxoazaheterocyclyl compounds which inhibit both Factor Xa and Factor IIa, to pharmaceutical compositions comprising these compounds, to intermediates ...
|
|
JP4831965B2 |
The present invention is directed to nanoparticulate compositions comprising statin such as lovastatin or simvastatin including surface stabilizer. The statin particles of the composition have an effective average particle size of less t...
|
|
JP4832015B2 |
|
|
JP4819226B2 |
The invention provides a method of reducing postoperative complications of cardiopulmonary bypass (CPB) surgery in which an effective amount of a methylol transfer agent, such as taurolidine, is administered to a patient in conjunction w...
|
|
JP4817088B2 |
The object of the present invention is to provide an embolizing material which is easily handleable and stable in quality and is solved by providing an embolizing material comprising an ester derivative of a polysaccharide having a weigh...
|
